NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
EMERYVILLE, Calif., March 7 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY), a mid-stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective products for the treatment and prevention of a wide range of bacterial, fungal, and viral infe...
MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series
Eleven of eleven wounds healed in 6 weeks or less
PRINCETON, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI ), a provider of advanced wound care products, announced today that its MEDIHONEY Dressings were the focus of a case series on eleven non-heal...
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
CARLSBAD, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals,
Inc. (Nasdaq: ISIS ) announced today that OncoGenex Pharmaceuticals, Inc.
provided positive survival results from a randomized Phase 2 clinical trial of
OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm...
SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
FRESNO, Calif., Oct. 29 /PRNewswire/ -- Cypress Systems, Inc., a Fresno
CA based biotechnology company, emphasizes that the SELECT TRIAL results --
that were announced yesterday -- used a form of selenium known as
selenomethionine. The SELECT TRIAL found no effects of either
Protein Shown to Play a Key Role in Normal Development of Nervous System
- Findings May Someday Inform Treatments for Spinal Cord, Other Nerve
PHILADELPHIA, Oct. 8 /PRNewswire-USNewswire/ -- A protein that enables
nerve cells to communicate with each other plays a key role in controlling
the developing nervous system. Research into how that protein hel...
Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months
BARCELONA, Spain, Sept. 2 /PRNewswire-FirstCall/ -- Final results from
a 24-week study presented today at a major medical meeting in Barcelona
suggest that investigational olanzapine long-acting injection (LAI)
therapeutic doses showed a maintenance of treatment benefit for up to six
CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
Believed by experts to be important for cervical cancer prevention
GRAZ, Austria, May 14 /PRNewswire-FirstCall/ -- New data from an
extended follow-up study show that GlaxoSmithKline (NYSE: GSK ) cervical
cancer candidate vaccine, CERVARIX(R) generates sustained high levels of
Evotec's EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks
Single-Dose, Volunteer fMRI Study Completed and Reported Today Dosing in Four Week Higher Repeat Dose Study Completed
HAMBURG, Germany and OXFORD, England, March 28 /PRNewswire-FirstCall/
-- Evotec (Frankfurt Stock Exchange: EVT) is pleased to announce the
preliminary findings of ...
Divine Corporation's Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
An Independent Study by the National Cancer Institute Revealed Divine No. 9
and Divine No. 8 to be Highly Effective in Inhibiting Viruses that Cause Cervical, Vaginal and Anal Cancers in vitro
ORLANDO, Fla., Jan. 22 /PRNewswire/ -- Divine Corporation announced
today an unprecedent...
SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
Inhibition Was Sustained and Dose-Dependent in Sub-Analysis of Phase II TRA- PCI Trial
ORLANDO, Fla., Nov. 7 /PRNewswire-FirstCall/ -- SCH 530348 (TRA), the
novel investigational antiplatelet agent in development by Schering-Plough
Corporation (NYSE: SGP ), was sho...
RediClinic Offers Affordable New Plan Clinically Shown to Double a Person's Chance to Stop Smoking
Retail Clinics Provide 12-week Plan to Help People Kick the Habit
HOUSTON, Aug. 2 /PRNewswire/ -- RediClinic LLC announced today that it
is offering an affordable new program to help people quit smoking. The
four-step "Stop Smoking for Good(TM)" plan, available at RediClinics
CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response
Against Hepatitis B Antigen in Animals
VIENNA, Va., May 01, 2007 /PRNewswire-FirstCall/ -- CEL-SCI
CORPORATION announces that CEL-1000 alone increased the immune
response against hepatitis B antigen, and that the combination of
CEL-1000 with MAS-1, a proprietary water-in-oil adjuvant delivery
system owned by Mercia Pharma, induced high...
Cethromycin Shown Effective Against Anthrax in Study
Advanced Life Sciences Achieves Key Endpoint in Primate Study
CHICAGO, May 02, 2007 /PRNewswire-FirstCall/ -- Advanced Life
Sciences Holdings, Inc. today announced that its novel respiratory
antibiotic, Cethromycin, was shown
to be effective in preventing
inhalation anthrax infection. This conclus...
RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds
Significant Promise for Treating Breast Cancer
IRVING, Texas--(BUSINESS WIRE)--May 15, 2007 - Reata
Pharmaceuticals, Inc. today announced the publication of an article
in the May 2007 issue of the journal Cancer Research showing that
RTA 402, the company's Phase 2 development candidate for cancer,
was highly effective in a rigorous animal model...
Innovative Cancer Drug MabThera Again Shown To Improve Survival
Rates In Patients With Lymphoma
Adding MabThera to first line chemotherapy significantly
increases patients_ overall survival
BASEL, Switzerland (21 May, 2007) _ In a study published
yesterday in the Journal of Clinical Oncology, MabThera (rituximab)
plus chemotherapy (MCP*) was shown
to significantly improve
survival in patie...
Efficacy and Safety Profile of Basilea's Alitretinoin for Severe
Refractory Chronic Hand Eczema Confirmed by Data Shown at European
BASEL, Switzerland, May 21, 2007 - Results from phase III
clinical trials and further human pharmacology studies were
presented at the 16th Congress of the European Academy of
Dermatology and Venereology (EADV). These data highlighted the
efficacy and safety profile of alitretinoin as a potential ...
CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response
Against Avian Flu Antigen in Animals
VIENNA, Va., May 23, 2007 /PRNewswire-FirstCall/ -- CEL-SCI
CORPORATION announces that CEL-1000 increased the immune response
against H5 avian influenza antigen in combination with MAS-1, a
water-in-oil adjuvant delivery system. These findings were
presented on May 23, 2007 by Dr. Daniel Zimmerman...
Gabapentin Shown Effective for Fibromyalgia Pain
BETHESDA, Md., June 11, 2007--New research supported by the
National Institutes of Healths National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS) shows that the
anticonvulsant medication gabapentin , which is used for certain
types of seizures, can be an effective t...
RTA 402 Shown to Protect Animals Against Toxicities of Standard
IRVING, Texas--(BUSINESS WIRE)--Jun 29, 2007 - Reata
Pharmaceuticals, Inc. today announced the presentation of new
preclinical data showing their lead anti-cancer agent, the
Synthetic Triterpenoid RTA 402, is effective at protecting against
common toxicities caused by traditional cancer treatments....
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
...val. Currently no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Vectibix. Vectibix has not shown
a treatment benefit for patients whose tumors had KRAS mutations in codon 12 or 13.
In December 2007, the EMEA granted a conditional marketin...
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
... small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's technology has been shown
to increase oral bioavailability and inhibit penetration across the blood-brain barrier, an important potential advance for small molecule therapies. ...
ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer
...anitumumab) and Erbitux (cetuximab). On July 17, 2009, the FDA noted that, "retrospective analyses of metastatic colorectal cancer trials have not shown
a treatment benefit for Erbitux/Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13," and that the use of the drugs is not recomm...
Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
...activator of AMPK (adenosine monophosphate activated protein kinase)
for the treatment of diabetes and metabolic diseases. Activation of AMPK has
to lower fasting blood glucose levels and improve glucose disposal
following a glucose challenge, two key goals in the management of type 2
Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
...erase P1-1 which in turn facilitates the activation of JNK kinase, a key regulator of cellular growth and differentiation of blood. TELINTRA has been shown
to stimulate normal multilineage differentiation of blood stem cell precursors and induce cancer cell death in human leukemia cell lines. Additional ...
Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
...oLindac , a novel DACH platinum drug that has shown
to be active in many solid tumors in human clinica... ProLindac is a novel DACH platinum drug that has shown
to be active in many solid tumors in human clinica...ac is a novel DACH platinum prodrug which has been shown
to be active in a wide variety of solid tumors in ...
Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
...e potent than Pharmasset's first generation nucleoside polymerase inhibitor, RG7128 (formerly known as R7128). In vitro studies of PSI-7851 have not shown
evidence of any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. Like RG7128, PSI-7851 has demonstrated...
Is Your Hair Taking a Break?
...he U.S. Food and Drug Administration (FDA) for female-pattern hair loss. Minoxidil 5% is only FDA-approved for male-pattern hair loss, but it has been shown
to be very effective in women as well. Both the 2% and 5% solutions are available over-the-counter. While minoxidil does not grow new hair, it works b...
Diabetes Gene Raises Odds of Lower Birth Weight
PHILADELPHIA, July 29 /PRNewswire-USNewswire/ -- Pediatric researchers have found that a gene previously shown
to be involved in the development of type 2 diabetes also predisposes children to having a lower birth weight. The finding sheds light on a possible g...
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
"Our objective with R788 in RA is to position the product after methotrexate and before biological therapies are used. We have shown
excellent results in that patient population in our earlier TASKi1 and TASKi2 studies, and we believe that patient population represents the large mar...
July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals
...aken only under a doctor's supervision.
Vitamin C: Studies have shown
that eating food high in vitamin C can lower rates of cancer and heart dise...her vitamin C supplements provide the same benefits.
Studies have shown
that vitamin C supplements, taken with some other antioxidants and zinc, ma...
National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness
... glutathione levels, a hallmark of drug-resistant tumors. Brostallicin was shown
to affect DNA in both dividing and quiescent cells. Its actions can be foll...stallicin, a novel synthetic second-generation DNA minor groove binder, has shown
potent cancer killing activity, and has demonstrated synergism in combinati...
UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201
...ir and cell proliferation. By inhibiting the enzymatic activity of PARP, BSI-201 significantly enhances the anti-tumor effects of chemotherapy and has shown
promising safety and efficacy results in patients with solid tumors.
"We are extremely pleased to be launching the Phase 3 clinical trial so ...
New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
...se in combination with other antiretroviral agents for the treatment of HIV infection.
VIRAMUNE does not cure HIV or AIDS, and has not been shown
to reduce the risk of passing HIV to others through sexual contact or blood contamination.
VIRAMUNE can cause severe liver disease and skin ...
Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
...ified form of the synthetic guanylhydrozone, semapimod. Semapimod has been shown
to inhibit the signal transduction pathways that lead to the production of ... led to human clinical trials. An intravenous formulation of semapimod was shown
to have significant anti-inflammatory activity in Phase II clinical trials ...
Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results
... 90 clinical sites in 13 countries, primarily in Asia, South America and Eastern Europe, were enrolled in the trial.
"This is the first drug shown
to be effective in ameliorating the signs and symptoms of lupus in decades," said Daniel J. Wallace, MD, clinical professor of medicine at the David G...
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
A clinically and statistically significant improvement was shown
patient response rate for belimumab plus standard of care, vs.
... patient response rate
were consistent with the overall improvement shown
for the primary
-- Results for prespecified major s...
AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine
...l immunogenicity studies of its H1N1 (swine) influenza vaccine and will manufacture clinical trial material by the end of the month. This vaccine has shown
good production yields as well as excellent immunogenicity, even after just a single inoculation.
"Our vaccine platform provides several pote...
BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
... spread of influenza within a host. Peramivir has demonstrated clinical activity and safety in prior human studies. In laboratory tests, peramivir has shown
activity against various viral strains, including the novel influenza A (H1N1) virus. In the U.S., BioCryst is preparing plans for additional Phase 3...
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
...alth and Human Services guidelines for antiretroviral therapy. Additionally, like vicriviroc, it is administered as a once daily dose and it has been shown
to have a more favorable lipid safety profile than other drugs in the PI class.
The study is being sponsored by Schering-Plough with suppor...
University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
SAN DIEGO and ANN ARBOR, Mich., July 13 /PRNewswire-FirstCall/ -- Results from a study published by the University of Michigan have shown
that as many as 15% of women in the study group determined to be negative for the presence of human papillomavirus (HPV) in the cervix, via the most c...